Novel nano-encapsulation of probucol in microgels: scanning electron micrograph characterizations, buoyancy profiling, and antioxidant assay analyses. (12th November 2018)

• Record Type: Journal Article
• Authors: Mooranian, Armin; Zamani, Nassim; Mikov, Momir; Goločorbin-Kon, Svetlana; Stojanovic, Goran; Arfuso, Frank; Al-Salami, Hani
• Is Part Of: Artificial cells, nanomedicine, and biotechnology. Volume 46(2018)Supplement 3
• Page Start: S741
• Page End: S747
• Publication Date: 2018-11-12
• Subjects: Probucol -- microencapsulation -- chenodeoxycholic acid -- oxidative stress -- topographic analysis -- diabetes; Artificial cells -- Periodicals; Nanotechnology -- Periodicals; Blood substitutes -- Periodicals; Tissue engineering -- Periodicals; Molecules -- Periodicals; Biotechnology -- Periodicals; 615.39
• DOI: 10.1080/21691401.2018.1511571
• Languages: English
• ISSNs: 2169-1401

Abstract

Abstract: Smart polymers such as Eudragit (ED) have shown potential applications in oral drug delivery and targeted release. Probucol (PB) is a lipophilic drug used for hypercholesterolemia and possesses desirable antidiabetic effects such as antioxidant and cell protective effects. PB is highly hydrophobic and has poor bioavailability with significant inter- and intra-patient absorption, limiting its clinical applications in diabetes. This study aimed to design and analyse new PB-ED formulations with or without the absorption-enhancer chenodeoxycholic acid (CDCA). Sodium alginate-based microcapsules containing three different ED polymers (NM30D, RL30D and RS30D) were investigated with or without CDCA via scanning electron microscopy, energy dispersive X-ray spectroscopy (EDXR), confocal microscopy, osmotic stability, mechanical properties, buoyancy, release profiles (pH: 7.4), thermal stability and antioxidant effects. The effects of microcapsules on pancreatic β-cell survival, function, inflammatory profile and PB cellular uptake were analysed. All microcapsules showed uniform morphology and surface topography with CDCA being distributed evenly throughout the microcapsules. Osmotic stability was significantly improved in PB-NM30D and PB-RL30D microcapsules ( p < .01 and p < .05, respectively), and PB-NM30D microcapsules displayed low buoyancy ( p < .01). CDCA improved PB-NM30D effects on pancreatic β-cell function and bioenergetics, which suggests potential application of PB-NM30D-CDCA in PB delivery and diabetes treatment.